

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/637,512	08/11/2000	Stanley M. Goldin	42,982 C3-CPA-C 1159	
75	90 10/22/2002			
PETER F. CORLESS EDWARDS & ANGELL, LLP P.O. BOX 9169			EXAMINER	
			O SULLIVAN, PETER G	
BOXTON, MA 02209			ART UNIT	PAPER NUMBER
			1621	10
			DATE MAILED: 10/22/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. **09/637,512**

Applicant(s)

Goldin et al.

•	Office Action Summary	Evenine	T A = 4 1 1 = 14			
	<u> </u>	Examiner Peter O'Sullivan	Art Unit 1621			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
	for Reply		F • · ·			
THE - Extens mailing - If the - If NO : - Failure - Any re	HORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. In this communication. In period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a reply within the set or extended period for reply within the set or extended period for reply will, by statute, cause the reply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	n no event, however, may a reply be timely filed the statutory minimum of thirty (30) days will be and will expire SIX (6) MONTHS from the meilin the application to become ABANDONED (35 U.S.	be considered timely. ling date of this comm			
Status						
1) 💢	Responsive to communication(s) filed on Jul 8, 200			•		
2a) 🗌	This action is FINAL . 2b) 💢 This act	ction is non-final.				
3) ☐ Disposi	closed in accordance with the practice under Ex pa	except for formal matters, prose arte Quayle, 1935 C.D. 11; 453	cution as to the O.G. 213.	he merits is		
=	ition of Claims					
	Claim(s) <u>25-31</u>					
_	4a) Of the above, claim(s) 28	is/ar/	e withdrawn f	from consideration.		
5) 🗆			is/are allowed	i.		
6) 💢	Claim(s) <u>25-27 and 29-31</u>					
7) 🗆	Claim(s)					
8) 🗆	Claims					
	ation Papers					
9) 🗌	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are	a) □ accepted or b) □ objecte	ed to by the Ex	xaminer.		
	Applicant may not request that any objection to the d	drawing(s) be held in abeyance. See	e 37 CFR 1.85((a).		
11)□						
_	If approved, corrected drawings are required in reply t	to this Office action.				
12)	The oath or declaration is objected to by the Exami	iner.				
_	under 35 U.S.C. §§ 119 and 120					
	13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a)	☐ All b)☐ Some* c)☐ None of:					
	1. Certified copies of the priority documents have		•			
	2. Certified copies of the priority documents have			·		
	 Copies of the certified copies of the priority do application from the International Burea ee the attached detailed Office action for a list of the 	eau (PCT Rule 17.2(a)).	this National S	Stage		
	Acknowledgement is made of a claim for domestic		<u>~1</u>			
	The translation of the foreign language provisional		31.			
	Acknowledgement is made of a claim for domestic) and/or 121.			
Attachme	ent(s)	privilly chart size .	allajor			
		4) Interview Summary (PTO-413) Paper No.	lo(s)			
	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (P				
3) 🔲 Info	ormation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:				

Application/Control Number: 09/637,512

Art Unit: 1621

- 1. Claims 25-31 are pending in this application which should be reviewed for errors.

 Applicants are requested to send copies of the references listed in their information disclosure statement with their next response. Claim 28 is held withdrawn from consideration as embracing non-elected subject matter.
- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

Claims 25-27 and 29-31 are again rejected under 35 U.S.C. 103(a) as being unpatentable over Douglas et al. '077 for the reasons of record. Applicants' arguments have been given due consideration but are found non-persuasive. In the generic formula of Douglas et al. X1 and X2 may be substituents overlapping applicants' and R may be aryl. R1-R3 may be hydrogen.

Douglas et al. disclose 1-cyclopropylmethyl-1-(2,6-dichlorophenyl) guanidine which is close to

Application/Control Number: 09/637,512

Page 3

Art Unit: 1621

applicants' compounds. Douglas et al. disclose the equivalency of cycloalkyl to aryl for their R substitutent (s. Col. 1, ll. 64 and 65). That Douglas et al. exemplify an N,N-disubstituted compound shows they clearly contemplated these compounds as part of their invention.

- Claims 25-27 and 29-31 are again rejected under 35 U.S.C. 103(a) as being unpatentable 4. over Weber et al. '976, taken with Durant et al., '675, and Durant et al., '604. Weber et al. disclose N,N' disubstituted guanidines wherein the substituents may be aryl or aralkyl optionally substituted by applicants' substituents. The compounds of Weber et al. '976 have utility in the treatment of stroke, neurodegenerative diseases, etc., but differ from applicants' compounds as being N,N-disubstituted, not N,N'-disubstituted. Newly cited Durant et al., '675, and Durant et al., '604, are relied on to teach that one nitrogen may have two substitutents and the others none or there may be N,N' disubstitution in similar compounds useful in the treatment of stroke, neurodegenerative diseases, etc. It would have been prima facie obvious at the time the invention was made to one of ordinary skill in the art to start with the teaching of the cited references, but to make N,N-disubstituted compounds and to expect them to be useful in the treatment of stroke, neurodegenerative diseases, etc.
- 5. No claim is allowed.
- Any inquiry concerning this communication should be directed to Peter O'Sullivan at 6. telephone number (703) 308-4526.